ERBB2 and breast cancer: Twenty-five QIs (39.7%) related to IHC testing, florescence in situ hybridisation (FISH) testing, or appropriateness of treatment linked to human epidermal growth factor receptor 2 (HER-2), oestrogen receptor (ER), and progesterone (PR) status in breast cancer patients [26], [30], [33], [36], [37], [38], [40].